Showing results (91-100 of 176) with videos related to

Sort By:
Pageof 18
Gynecologic Oncology|April 1, 2015
Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgeryPierluigi Benedetti Panici, Violante Di Donato, Margherita Fischetti, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Low-grade versus high-grade serous ovarian cancer: comparison of surgical outcomes after secondary cytoreductive surgerySerena Cappuccio, Claudia Marchetti, Defne Alara Altıntaş, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|May 20, 2015
Tumor infiltrating lymphocytes in ovarian cancerMaria Luisa Gasparri, Rukset Attar, Innocenza Palaia, et al.
Anti-Cancer Drugs|August 5, 2015
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: a multicentric Italian experienceFrancesca Martella, Vanda Salutari, Claudia Marchetti, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 5, 2022
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patientsMarianna Buttarelli, Alessandra Ciucci, Fernando Palluzzi, et al.
Cancer Research and Treatment|July 21, 2017
Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical CancerClaudia Marchetti, Francesca De Felice, Anna Di Pinto, et al.
Expert Opinion on Investigational Drugs|July 30, 2019
Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancerErlisa Bardhi, Claudia Marchetti, Annalisa Scopelliti, et al.
Expert Opinion on Pharmacotherapy|May 20, 2017
Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapiesFederica Tomao, Claudia Marchetti, Alessia Romito, et al.
Critical Reviews in Oncology/Hematology|March 19, 2015
Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)Claudia Marchetti, Maria Luisa Gasparri, Ilary Ruscito, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patientsMatteo Bruno, Adriana Ionelia Apostol, Serena Maria Boccia, et al.
Pageof 18